Phase 1 Clinical Trial

Burlington, Massachusetts, U.S., September 10, 2026 Consano Bio, Inc. has announced the publication of peer-reviewed nonclinical research evaluating C-1101,...

Boston, Massachusetts, U.S., and Vancouver, British Columbia, Canada, September 8, 2026 Alpha-9 Oncology has announced the dosing of the...

Hong Kong, September 8, 2026 Ascletis Pharma Inc. has announced the initiation of a U.S. Phase 1 clinical trial...

Zhuhai, China — September 7, 2026 Rezubio announced the successful first cohort dosing of RZ-520 in a Phase 1...

Austin, Texas – August 27, 2026 Natera and Angiex have entered a new collaboration to assess treatment response to...

Tokyo, Japan – August 27, 2026 Daiichi Sankyo has entered a new phase of oncology development with the first...

RALEIGH, N.C. – August 27, 2026 Slate Medicines Inc. announced that the first participant has been dosed in its...

SYDNEY, Australia, August 26, 2026 HaemaLogiX Ltd has announced a key clinical development milestone with the first patient successfully...

PALO ALTO, Calif., August 18, 2026 Amygdala Neurosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has...

BURLINGTON, Mass., August 18, 2026 Consano Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...